Daewoong Pharma
KRX:069620

Watchlist Manager
Daewoong Pharma Logo
Daewoong Pharma
KRX:069620
Watchlist
Price: 129 100 KRW 0.08% Market Closed
Market Cap: 1.5T KRW
Have any thoughts about
Daewoong Pharma?
Write Note

Intrinsic Value

The intrinsic value of one Daewoong Pharma stock under the Base Case scenario is 213 530.48 KRW. Compared to the current market price of 129 100 KRW, Daewoong Pharma is Undervalued by 40%.

Intrinsic Value
213 530.48 KRW
Undervaluation 40%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Daewoong Pharma

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Daewoong Pharma cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Daewoong Pharma?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Daewoong Pharma

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Daewoong Pharma

Provide an overview of the primary business activities
of Daewoong Pharma.

What unique competitive advantages
does Daewoong Pharma hold over its rivals?

What risks and challenges
does Daewoong Pharma face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Daewoong Pharma.

Provide P/S
for Daewoong Pharma.

Provide P/E
for Daewoong Pharma.

Provide P/OCF
for Daewoong Pharma.

Provide P/FCFE
for Daewoong Pharma.

Provide P/B
for Daewoong Pharma.

Provide EV/S
for Daewoong Pharma.

Provide EV/GP
for Daewoong Pharma.

Provide EV/EBITDA
for Daewoong Pharma.

Provide EV/EBIT
for Daewoong Pharma.

Provide EV/OCF
for Daewoong Pharma.

Provide EV/FCFF
for Daewoong Pharma.

Provide EV/IC
for Daewoong Pharma.

Show me price targets
for Daewoong Pharma made by professional analysts.

What are the Revenue projections
for Daewoong Pharma?

How accurate were the past Revenue estimates
for Daewoong Pharma?

What are the Net Income projections
for Daewoong Pharma?

How accurate were the past Net Income estimates
for Daewoong Pharma?

What are the EPS projections
for Daewoong Pharma?

How accurate were the past EPS estimates
for Daewoong Pharma?

What are the EBIT projections
for Daewoong Pharma?

How accurate were the past EBIT estimates
for Daewoong Pharma?

Compare the revenue forecasts
for Daewoong Pharma with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Daewoong Pharma and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Daewoong Pharma against its competitors.

Analyze the profit margins
(gross, operating, and net) of Daewoong Pharma compared to its peers.

Compare the P/E ratios
of Daewoong Pharma against its peers.

Discuss the investment returns and shareholder value creation
comparing Daewoong Pharma with its peers.

Analyze the financial leverage
of Daewoong Pharma compared to its main competitors.

Show all profitability ratios
for Daewoong Pharma.

Provide ROE
for Daewoong Pharma.

Provide ROA
for Daewoong Pharma.

Provide ROIC
for Daewoong Pharma.

Provide ROCE
for Daewoong Pharma.

Provide Gross Margin
for Daewoong Pharma.

Provide Operating Margin
for Daewoong Pharma.

Provide Net Margin
for Daewoong Pharma.

Provide FCF Margin
for Daewoong Pharma.

Show all solvency ratios
for Daewoong Pharma.

Provide D/E Ratio
for Daewoong Pharma.

Provide D/A Ratio
for Daewoong Pharma.

Provide Interest Coverage Ratio
for Daewoong Pharma.

Provide Altman Z-Score Ratio
for Daewoong Pharma.

Provide Quick Ratio
for Daewoong Pharma.

Provide Current Ratio
for Daewoong Pharma.

Provide Cash Ratio
for Daewoong Pharma.

What is the historical Revenue growth
over the last 5 years for Daewoong Pharma?

What is the historical Net Income growth
over the last 5 years for Daewoong Pharma?

What is the current Free Cash Flow
of Daewoong Pharma?

Discuss the annual earnings per share (EPS)
trend over the past five years for Daewoong Pharma.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Daewoong Pharma

Current Assets 574.8B
Cash & Short-Term Investments 137.7B
Receivables 178B
Other Current Assets 259.2B
Non-Current Assets 1.2T
Long-Term Investments 273.9B
PP&E 521.9B
Intangibles 297.5B
Other Non-Current Assets 102.2B
Current Liabilities 667.1B
Accounts Payable 101.1B
Accrued Liabilities 26.6B
Short-Term Debt 167.4B
Other Current Liabilities 372B
Non-Current Liabilities 335.9B
Long-Term Debt 66.9B
Other Non-Current Liabilities 268.9B
Efficiency

Earnings Waterfall
Daewoong Pharma

Revenue
1.4T KRW
Cost of Revenue
-691B KRW
Gross Profit
725.7B KRW
Operating Expenses
-587.7B KRW
Operating Income
137.9B KRW
Other Expenses
-34.4B KRW
Net Income
103.6B KRW

Free Cash Flow Analysis
Daewoong Pharma

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Daewoong Pharma's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
Positive 3-Years Revenue Growth
Positive ROE
54/100
Profitability
Score

Daewoong Pharma's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Daewoong Pharma's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Positive Net Debt
Average Altman Z-Score
50/100
Solvency
Score

Daewoong Pharma's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Daewoong Pharma

Wall Street analysts forecast Daewoong Pharma stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Daewoong Pharma is 195 257.14 KRW with a low forecast of 161 600 KRW and a high forecast of 231 000 KRW.

Lowest
Price Target
161 600 KRW
25% Upside
Average
Price Target
195 257.14 KRW
51% Upside
Highest
Price Target
231 000 KRW
79% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Daewoong Pharma?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Daewoong Pharma is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Daewoong Pharma Logo
Daewoong Pharma

Country

Korea

Industry

Pharmaceuticals

Market Cap

1.5T KRW

Dividend Yield

0%

Description

Daewoong Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2002-11-01. The firm's products mainly include antihypertensive drugs, antianemic agents, antidiabetic agents, antiemetic agents, antihistamine agents, antimicrobials, antineoplastics, antiobesity agents, antipyretic agents, analgesic agents, anti-inflammatory agents, biosimilars, remedies for bone and joint diseases, cardiovascular treatments, central nervous system treatments, digestive agents, dermatologic agents, gastrointestinal agents, health supplements and respiratory remedies, among others. The firm distributes its products in domestic and overseas markets.

Contact

GYEONGGI-DO
Hwaseong
35-14, Jeyakgongdan 4-gil, Hyangnam-eup
+8225508800
www.daewoong.co.kr

IPO

2002-11-01

Employees

-

Officers

CEO & Executive Director
Mr. Seongsoo Park
Executive Director
Eunkyeong Park

See Also

Discover More
What is the Intrinsic Value of one Daewoong Pharma stock?

The intrinsic value of one Daewoong Pharma stock under the Base Case scenario is 213 530.48 KRW.

Is Daewoong Pharma stock undervalued or overvalued?

Compared to the current market price of 129 100 KRW, Daewoong Pharma is Undervalued by 40%.

Back to Top